- Home
- NUVL
NUVL
Nuvalent Inc.
as of 01-20-2026 3:52pm EST
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 7.1B | IPO Year: | 2021 |
| Target Price: | $135.00 | AVG Volume (30 days): | 548.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $55.53 - $112.88 | Next Earning Date: | 02-26-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered NUVL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Nuvalent Inc. (NUVL)
Chief Legal Officer
Avg Cost/Share
$97.49
Shares
2,589
Total Value
$251,559.68
Owned After
42,134
Chief Development Officer
Avg Cost/Share
$97.49
Shares
3,181
Total Value
$309,081.30
Owned After
40,842
Chief Financial Officer
Avg Cost/Share
$97.49
Shares
3,181
Total Value
$309,081.30
Owned After
81,733
Chief Medical Officer
Avg Cost/Share
$97.49
Shares
3,181
Total Value
$309,081.30
Owned After
56,990
President and CEO
Avg Cost/Share
$97.49
Shares
9,543
Total Value
$927,243.90
Owned After
278,629
Chief Scientific Officer
Avg Cost/Share
$97.49
Shares
2,664
Total Value
$258,847.87
Owned After
65,888
Chief Legal Officer
Avg Cost/Share
$97.35
Shares
4,363
Total Value
$424,597.91
Owned After
42,134
Chief Development Officer
Avg Cost/Share
$97.35
Shares
4,236
Total Value
$412,239.09
Owned After
40,842
Chief Financial Officer
Avg Cost/Share
$97.35
Shares
4,236
Total Value
$412,239.09
Owned After
81,733
Chief Medical Officer
Avg Cost/Share
$97.35
Shares
4,236
Total Value
$412,239.09
Owned After
56,990
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Miller Deborah Ann | NUVL | Chief Legal Officer | Jan 6, 2026 | Sell | $97.49 | 2,589 | $251,559.68 | 42,134 | |
| Noci Darlene | NUVL | Chief Development Officer | Jan 6, 2026 | Sell | $97.49 | 3,181 | $309,081.30 | 40,842 | |
| Balcom Alexandra | NUVL | Chief Financial Officer | Jan 6, 2026 | Sell | $97.49 | 3,181 | $309,081.30 | 81,733 | |
| Turner Christopher Durant | NUVL | Chief Medical Officer | Jan 6, 2026 | Sell | $97.49 | 3,181 | $309,081.30 | 56,990 | |
| Porter James Richard | NUVL | President and CEO | Jan 6, 2026 | Sell | $97.49 | 9,543 | $927,243.90 | 278,629 | |
| Pelish Henry E. | NUVL | Chief Scientific Officer | Jan 6, 2026 | Sell | $97.49 | 2,664 | $258,847.87 | 65,888 | |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Jan 5, 2026 | Sell | $97.35 | 4,363 | $424,597.91 | 42,134 | |
| Noci Darlene | NUVL | Chief Development Officer | Jan 5, 2026 | Sell | $97.35 | 4,236 | $412,239.09 | 40,842 | |
| Balcom Alexandra | NUVL | Chief Financial Officer | Jan 5, 2026 | Sell | $97.35 | 4,236 | $412,239.09 | 81,733 | |
| Turner Christopher Durant | NUVL | Chief Medical Officer | Jan 5, 2026 | Sell | $97.35 | 4,236 | $412,239.09 | 56,990 |
Compare NUVL vs Leading Stocks
See how NUVL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NUVL Nuvalent Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.